Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Specialty pharmaceutical firm Ipsen has announced that the European Commission has granted marketing authorization for Adenuric.
Subscribe to our email newsletter
Adenuric (febuxostat) 80mg and 120mg tablets are indicated for the treatment of chronic hyperuricaemia for conditions in which urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).
Adenuric will be marketed by Ipsen in France. Outside France, the commercialization of the product will be partnered.